Advertisement

Annals of Hematology

, Volume 91, Issue 11, pp 1823–1824 | Cite as

Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes

  • Adriano Salaroli
  • Giuseppina Loglisci
  • Alessandra Serrao
  • Giuliana Alimena
  • Massimo BrecciaEmail author
Letter to the Editor

Dear Editor,

A minority of patients with chronic myeloproliferative disease have constitutive activation of the gene for PDGFRβ; this is usually caused by t(5;12)(q33;p13) translocation associated with a TEL-PDGFRβ fusion gene encoding for a tyrosine kinase receptor which can be inhibited by imatinib. Several reports [1, 2, 3] have suggested that imatinib can affect fasting glucose (FG) level in CML or gastrointestinal stromal tumors (GIST) patients with type II diabetes. Here, we report a patient with TEL-PDGFRβ rearrangement affected by concomitant type 1 diabetes who was treated with imatinib at 400 mg daily and experienced symptomatic FG reduction requiring insulin dose decrease.

A 27-year-old male referred to our institute for asymptomatic isolated leukocytosis (35 × 109/l). While peripheral blood molecular evaluation for BCR-ABL rearrangement was negative, conventional cytogenetic analysis showed a t(5;12)(q33;q13) in 13 out of 22 metaphases analyzed. Qualitative molecular...

Keywords

Imatinib Gastrointestinal Stromal Tumor Imatinib Therapy Imatinib Treatment Symptomatic Hypoglycemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Mokhtari D, Welsh N (2009) Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. Clin Sci (Lond) 118:241–247CrossRefGoogle Scholar
  2. 2.
    Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J, Drabick JJ (2011) Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and non-diabetic patients in general clinical practice. J Oncol Pharm Pract 17:197–202PubMedCrossRefGoogle Scholar
  3. 3.
    Breccia M, Muscaritoli M, Aversa Z, Mandelli F, Alimena G (2004) Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol 22:4653–4655PubMedCrossRefGoogle Scholar
  4. 4.
    Breccia M, Alimena G (2009) The metabolic consequences of imatinib mesylate: changes on glucose, lypidic and bone metabolism. Leuk Res 33:871–875PubMedCrossRefGoogle Scholar
  5. 5.
    Guiteau J, Fanucchi M, Folpe A, Staley CA 3rd, Kooby DA (2006) Hypoglycemia in the setting of advanced gastrointestinal stromal tumor. Am Surg 72:1225–1230PubMedGoogle Scholar
  6. 6.
    Hamberg P, de Jong FA, Boonstra JG, van Doorn J, Verweji J, Sleijfer S (2006) Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib. J Clin Oncol 24:e30–e31PubMedCrossRefGoogle Scholar
  7. 7.
    Hägerkvist R, Sandler S, Mokhtari D, Welsh N (2007) Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic pre-conditioning. FASEB J 21:618–628PubMedCrossRefGoogle Scholar
  8. 8.
    Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino AC (2010) Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab 95:3763–3767PubMedCrossRefGoogle Scholar
  9. 9.
    Dingli D, Wolf RC, Vella A (2007) Imatinib and type 2 diabetes. Endocr Pract 13:126–130PubMedGoogle Scholar
  10. 10.
    Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA (2008) Tyrosine kinase inhibitors reverse type 1 diabetes in non-obese diabetic mice. Proc Natl Acad Sci U S A 105:18895–18900PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Adriano Salaroli
    • 1
  • Giuseppina Loglisci
    • 1
  • Alessandra Serrao
    • 1
  • Giuliana Alimena
    • 1
  • Massimo Breccia
    • 1
    • 2
    Email author
  1. 1.Department of Biotechnologies and Cellular HematologySapienza UniversityRomeItaly
  2. 2.Department of Human Biotechnologies and HematologySapienza UniversityRomeItaly

Personalised recommendations